WASHINGTON, July 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new ...

WASHINGTON, July 17, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new ...

60 Degrees Pharmaceuticals announced a public offering pricing at $1.90 per share, aiming to raise approximately $5 million.

WASHINGTON, July 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for ...

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion ...

60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions ...

Additionally, 60 Degrees Pharmaceuticals introduced a new 8-count bottle packaging for ARAKODA, aimed at travelers seeking malaria prophylaxis, now available through major retail pharmacies.

$5 million received upfront with up to an additional $5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrant ...

In other recent news, 60 Degrees Pharmaceuticals announced that it has identified a potential market of $245 million annually for its drug ARAKODA (tafenoquine) aimed at treating human babesiosis ...

60 Degrees Pharmaceuticals, Inc., a pharmaceutical company focused on developing new medicines for infectious diseases, announced its entry into a sponsored research agreement with Tulane University ...